N/A
N=62
Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder
Transmission, Blood, Recipient/Donor
Bottom Line
View on ClinicalTrials.gov: NCT02476851 ↗Enrolled (actual)
62
Serious AEs
0.0%
Results posted
Apr 2022
Primary outcome: Primary: Plasma Supernatant Hemoglobin — 26.8; 28.0 mg/dL
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- POLFA (Needle Assembly) (Device); Kawasumi (Needle Assembly) (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Haemonetics Corporation
- Primary completion
- Jul 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Plasma Supernatant Hemoglobin |
26.8; 28.0 | — |
Summary
This study evaluates whether whole blood transferred through the new POLFA needle assembly meets supernatant hemoglobin acceptability standards.
Eligibility Criteria
Eligibility Criteria:
- Study donor must be ≥ 18 years of age.
- Study donor must weigh ≥ 110 pounds.
- Study donor's body temperature must be ≤ 37.5°C / 99.5°F (oral).
- Study donor's hemoglobin must be ≥12.5 g/dL.
- Study donor's hematocrit must be ≥ 38%.
- Study donor must meet all criteria per respective site's Research Blood Donation Record (BDR).
- Study donor's most recent single RBC unit donation must have been ≥56 days prior to study donation.
- Study donor's most recent double RBC unit donation must have been ≥ 112 days prior to study donation.
- Study donor must have consented to study participation by reviewing and having expressed understanding the site-respective IRB-approved informed consent form prior to undergoing any study related procedures.
- Study donors must agree to report adverse events from the time of signing the informed consent to twenty-four hours following the end of their active study involvement.
- Study donors must not have experienced any of the following:
Physical trauma consistent with associated coagulopathy within the last 30 days, Surgery within the last 30 days, Known history of hypercoagulopathy (i.e., Factor V Leiden, Prothrombin G20210A, idiopathic venous thrombotic events, etc.).
- Female study donors must not be pregnant, expected to be pregnant or breastfeeding.
Exclusion Criteria - any individual not meeting the above criteria.
Data sourced from ClinicalTrials.gov (NCT02476851). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.